Abstract
Glioblastoma is the most common adult malignant primary brain tumor, and carries a dismal prognosis. After initial standard radiation therapy and chemotherapy with temozolomide, few standard chemotherapy options are available. In the last two decades, a growing understanding of molecular pathogenesis of glioblastoma has turned our focus toward targeted therapy. This review will discuss our current understanding of gliomagenesis and highlight the clinical attempts to manipulate these vital pathways, describing past and current studies, and future directions.
Keywords: Cell signaling, glioblastoma, gliomagenesis, monoclonal antibodies, targeted therapy, tyrosine kinase inhibitors.
Current Cancer Therapy Reviews
Title:Targeted Therapy for Glioblastoma: Lessons Learned and Future Directions
Volume: 11 Issue: 1
Author(s): Nicole A Shonka, Suprit Gupta and Pankaj K. Singh
Affiliation:
Keywords: Cell signaling, glioblastoma, gliomagenesis, monoclonal antibodies, targeted therapy, tyrosine kinase inhibitors.
Abstract: Glioblastoma is the most common adult malignant primary brain tumor, and carries a dismal prognosis. After initial standard radiation therapy and chemotherapy with temozolomide, few standard chemotherapy options are available. In the last two decades, a growing understanding of molecular pathogenesis of glioblastoma has turned our focus toward targeted therapy. This review will discuss our current understanding of gliomagenesis and highlight the clinical attempts to manipulate these vital pathways, describing past and current studies, and future directions.
Export Options
About this article
Cite this article as:
Shonka A Nicole, Gupta Suprit and Singh K. Pankaj, Targeted Therapy for Glioblastoma: Lessons Learned and Future Directions, Current Cancer Therapy Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/157339471101150706122425
DOI https://dx.doi.org/10.2174/157339471101150706122425 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents, Formulation and Characterization of Nanoliposomes
Recent Patents on Drug Delivery & Formulation Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Double Layered Hydroxides as Potential Anti-Cancer Drug Delivery Agents
Mini-Reviews in Medicinal Chemistry Role of Extracellular Vesicles in Glioma Progression: Deciphering Cellular Biological Processes to Clinical Applications
Current Topics in Medicinal Chemistry Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews Drug Delivery Systems and Strategies to Overcome the Barriers of Brain
Current Pharmaceutical Design A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Recent Developments in the Formulation of Nanoliposomal Delivery Systems
Current Nanomaterials Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Carbohydrates: Potential Sweet Tools Against Cancer
Current Medicinal Chemistry Structure-Activity Relationships of Biphalin Analogs and their Biological Evaluation on Opioid Receptors
Mini-Reviews in Medicinal Chemistry The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Interaction of Endocannabinoid Receptors with Biological Membranes
Current Medicinal Chemistry Microarray: An Approach for Current Drug Targets
Current Drug Metabolism Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies
Current Pharmaceutical Design Multicomponent 1,3-Dipolar Cycloaddition Reactions in the Construction of Hybrid Spiroheterocycles
Current Organic Chemistry Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets